Rapid Combo Antigen SARS-COV-2 Ag and Influenza Test, 1 piece, Montana Med The disease caused by coronavirus (SARS-CoV-2), also known as the COVID-19 virus, is an acute respiratory infectious disease. SARS-CoV-2 is a β-coronavirus, which is an enveloped, nonsegmented, positive-sense RNA virus. It is currently spread by human-to-human transmission through droplets or direct contact, asymptomatic infected people can also be an infectious source. The main manifestations include fever, fatigue, and dry cough. Nasal congestion, rhinorrhea, sore throat, myalgia, and diarrhea are found in a few cases Influenza (commonly known as the flu) is an acute, highly contagious viral infection of the respiratory tract. It is a highly contagious disease transmitted by coughing and sneezing through aerosolized droplets containing live virus. Outbreaks of influenza occur each year during the fall and winter months. Type A viruses are usually more widespread than type B viruses and are associated with the most serious influenza epidemics, while type B infections are usually milder. The availability of a rapid and cost-effective diagnostic test is essential to enable healthcare professionals to help diagnose patients and prevent further spread of the virus. Antigen tests will play a critical role in the fight against COVID-19. How to use: The SARS-CoV-2 & Influenza Antigen Combo Rapid Test is a rapid in vitro diagnostic test for the qualitative detection of SARS-CoV-21 and/or influenza A, influenza B antigen (AG) in human nasal swab specimens from individuals meeting the clinical and/or epidemiological criteria for COVID-19. The SARS-CoV-2 & Influenza Antigen Combo Rapid Test Influenza is intended for use as an aid in the diagnosis of SARS-CoV-2 infection and/or influenza with Influenza type A or type B virus. The product can be used in any laboratory environment and outpatient conditions that meet the requirements specified in the instructions for use and local regulations. The test provides preliminary results. Negative results should be combined with clinical observations, patient history, and epidemiological information. The test is not intended for use as a donor screening test for SARS-CoV-2. The SARS-CoV-2 & Influenza Antigen Combo Rapid Test contains two distinct membrane-type strips. The COVID-19 AG strip is pre-coated with immobilized anti-SARS-CoV-2 antibodies on the test line and murine monoclonal anti-chicken IgY on the control line. Two types of conjugates (gold-conjugated human IgG specific for SARS-CoV-2 AG and gold-conjugated chicken IgY) migrate up the chromatographic membrane and react with the anti-SARS-CoV-2 antibody and the anti-chicken IgY and murine monoclonal antibody strips, respectively. For a positive result, human IgG specific to SARSCoV-2 AG gold conjugate and anti-SARS-CoV-2 antibody will form a test line in the result window. Neither the test line nor the control line are visible in the result window before applying the patient sample. The Influenza A+B strip is composed of the following parts: sample well, reagent pad, reaction membrane and absorption pad. The reagent pad contains colloidal gold conjugated to monoclonal antibodies against influenza A and B viruses; The reaction membrane contains secondary antibodies to either Influenza type A or type B viruses. A visible control line is required to indicate a valid test result. Presentation: 1 piece